Table 1.

Landmark trials of immunotherapy in GI.

Name of trial	Title	Interventions	Phases
Colorectal Cancer
KEYNOTE 028	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer	Drug: Pembrolizumab	Phase 2
CheckMate 142	Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer	Drug: Nivolumab	Phase 2
CheckMate 142 (further analysis of subgroup)	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade	Drug: Nivolumab+ Ipilumumab	Phase 2
Gastroesophageal Cancer
ATTRACTION-2 CheckMate-032	A study of nivolumab by itself or nivolumab combined with ipilimumab in patients with advanced or metastatic solid tumors	Drug: Nivolumab	Phase 1-2
KEYNOTE-012 KEYNOTE-059	A study of pembrolizumab in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma	Drug: Pembrolizumab	Phase 2
NCT01585987	An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy	Drug: Ipilimumab	Phase 2
NCT01693562	A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.	Drug: MEDI4736	Phase 1-2